2 Mar 2018 15:01
BUZZ-Verona Pharma: Soars on positive data from mid-stage study
** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq-listed companies ** data a
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
VRP.L Share News (VRP)
VRP Share
Price
VRP Share
News
VRP Share
Chat
VRP Share
Trades
VRP
Live RNS
VRP Share
Charts
VRP Broker
Ratings
VRP Directors
Deals
VRP Financial
Diary
VRP
Fundamentals
VRP Short
Positions
VRP
Media
VRP.L Information
- There is currently no data for VRP
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Small caps round-up: Verona, Image Scan, Avia
Tue, 04th Sep 2012 08:58
Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a rapid widening of the airways, greater than a 15% increase in FEV1 (forced expiratory volume at 1 second). This magnitude of what medical professionals call a bronchodilator response was significantly larger than that produced by placebo and appeared to be at least equivalent to that produced by a standard dose of the industry-standard bronchodilator product in these patients. In addition, inhalation of the doses was well tolerated and did not cause any significant adverse effects.Image Scan, which provides two-dimensional and three-dimensional scanning gizmos to the security and industrial inspection markets, has landed a new industrial inspection system contract worth £138,000.Health-care software firm Avia has been given a vote of confidence by sector peer Advanced Computer Software Group (ACS), which is lending Avia £350,000 over three years at zero interest. ACS will have the option to convert the loan into a 29.9% stake in Avia, and has also been given the right to nominate a non-executive director to the Avia board. The funds will alleviate the working capital constraints Avia is currently experiencing.JH
More News
26 Sep 2016 09:39
Verona Pharma appoints sector veteran Morgan as CFO
(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c
Read more13 Sep 2016 12:04
Verona Pharma makes progress on new respiratory drug
(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr
Read more20 Jun 2016 15:02
20 Jun 2016 12:50
Verona Pharma secures funding for drug trial
(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new
Read more3 Jun 2016 12:52
Verona Pharma's shares fall as higher R&D costs widen FY loss
(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its
Read more15 Mar 2016 10:35
Verona Pharma excites with asthma trial results
(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu
Read more21 Jan 2016 13:31